Two Sigma Advisers’s Exelixis EXEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-222,690
Closed -$9.76M 726
2025
Q4
$9.76M Buy
222,690
+198,190
+809% +$8.2M 0.02% 552
2025
Q3
$1.01M Sell
24,500
-404,290
-94% -$16.3M ﹤0.01% 1456
2025
Q2
$18.9M Sell
428,790
-1,856,300
-81% -$74.2M 0.04% 349
2025
Q1
$84.4M Buy
2,285,090
+657,200
+40% +$23.4M 0.19% 113
2024
Q4
$54.2M Sell
1,627,890
-74,700
-4% -$2.42M 0.13% 159
2024
Q3
$44.2M Buy
1,702,590
+98,000
+6% +$2.44M 0.1% 180
2024
Q2
$36.1M Sell
1,604,590
-151,300
-9% -$3.36M 0.08% 223
2024
Q1
$41.7M Sell
1,755,890
-84,600
-5% -$1.88M 0.1% 215
2023
Q4
$44.2M Sell
1,840,490
-373,700
-17% -$8.12M 0.1% 197
2023
Q3
$48.4M Sell
2,214,190
-83,800
-4% -$1.75M 0.12% 167
2023
Q2
$43.9M Buy
2,297,990
+626,600
+37% +$12.1M 0.11% 193
2023
Q1
$32.4M Buy
1,671,390
+560,300
+50% +$9.76M 0.08% 229
2022
Q4
$17.8M Buy
1,111,090
+2,700
+0.2% +$44K 0.05% 373
2022
Q3
$17.4M Sell
1,108,390
-716,500
-39% -$13.8M 0.05% 355
2022
Q2
$38M Sell
1,824,890
-219,100
-11% -$4.52M 0.11% 200
2022
Q1
$46.3M Sell
2,043,990
-253,600
-11% -$4.95M 0.12% 173
2021
Q4
$42M Buy
2,297,590
+81,100
+4% +$1.55M 0.11% 175
2021
Q3
$46.9M Buy
2,216,490
+952,900
+75% +$17.7M 0.12% 169
2021
Q2
$23M Buy
1,263,590
+629,400
+99% +$14.7M 0.06% 300
2021
Q1
$14.3M Buy
634,190
+153,200
+32% +$3.46M 0.04% 448
2020
Q4
$9.65M Buy
480,990
+1,300
+0.3% +$27.2K 0.03% 581
2020
Q3
$11.7M Sell
479,690
-507,500
-51% -$11.8M 0.03% 492
2020
Q2
$23.4M Buy
987,190
+887,855
+894% +$20.6M 0.07% 287
2020
Q1
$1.71M Sell
99,335
-184,300
-65% -$3.37M 0.01% 1196
2019
Q4
$5M Sell
283,635
-391,200
-58% -$6.63M 0.01% 854
2019
Q3
$11.9M Buy
674,835
+187,300
+38% +$3.79M 0.03% 491
2019
Q2
$10.4M Buy
+487,535
New +$10.2M 0.03% 573
2019
Q1
Sell
-11,631
Closed -$229K 2342
2018
Q4
$229K Buy
+11,631
New +$207K ﹤0.01% 2086
2018
Q3
Sell
-1,081,321
Closed -$23.3M 2281
2018
Q2
$23.3M Sell
1,081,321
-624,400
-37% -$12.9M 0.06% 357
2018
Q1
$37.8M Sell
1,705,721
-1,876,800
-52% -$51.9M 0.1% 253
2017
Q4
$109M Sell
3,582,521
-566,817
-14% -$15.1M 0.29% 94
2017
Q3
$101M Sell
4,149,338
-13,126
-0.3% -$349K 0.28% 93
2017
Q2
$103M Sell
4,162,464
-346,757
-8% -$7.34M 0.34% 65
2017
Q1
$97.7M Buy
4,509,221
+1,080,321
+32% +$22M 0.32% 71
2016
Q4
$51.1M Buy
3,428,900
+1,632,797
+91% +$23.6M 0.2% 120
2016
Q3
$23M Buy
1,796,103
+817,313
+84% +$8.84M 0.1% 231
2016
Q2
$7.64M Buy
978,790
+270,400
+38% +$1.56M 0.04% 427
2016
Q1
$2.83M Buy
708,390
+446,200
+170% +$1.89M 0.02% 664
2015
Q4
$1.48M Buy
262,190
+60,694
+30% +$340K 0.01% 863
2015
Q3
$1.13M Buy
+201,496
New +$1.1M 0.01% 961
2015
Q1
Sell
-24,290
Closed -$35K 2053
2014
Q4
$35K Buy
+24,290
New +$37.9K ﹤0.01% 2378

Other funds holding EXEL

Two Sigma Advisers's EXEL Position: Q1 2026 in Review

Two Sigma Advisers sold out of Exelixis (EXEL) in Q1 2026, closing a stake of 222,690 shares — an estimated $9.76M sold.

Two Sigma Advisers first reported a position in EXEL in Q4 2014 and held it in 41 quarters. The position peaked at $109M in Q4 2017. 694 funds tracked by Wall St. Rank hold EXEL as of Q1 2026.

  • Two Sigma Advisers reported no remaining Exelixis position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 222,690 Exelixis shares in Q1 2026, an estimated $9.76M.
  • Two Sigma Advisers first reported a position in Exelixis in Q4 2014 and held it in 41 quarters.
  • Two Sigma Advisers's Exelixis position peaked at $109M in Q4 2017.
  • 694 funds tracked by Wall St. Rank held Exelixis as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.